CKI-7

• Description:

  CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1) . CKI-7 has a much weaker effect on casein kinase II and other protein kinases[1][2][3][4].

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Casein Kinase; CDK; Ribosomal S6 Kinase (RSK) ; SGK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cki7.html

• Purity:

  99.97

• Solubility:

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=S(C1=CC=C(Cl)C2=C1C=NC=C2)(NCCN)=O.[H]Cl.[H]Cl

• Molecular Formula:

  C11H14Cl3N3O2S

• Molecular Weight:

  358.67

• Precautions:

  H301

• References & Citations:

  [1] Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122 (Pt 17) :3169-79.|[2]Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11) : 2668.|[3]Chijiwa T, et al. A newly synthesized selective casein kinase I inhibitor, N- (2-aminoethyl) -5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J Biol Chem. 1989 Mar 25;264 (9) :4924-7.|[4]Rena G, et al. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004 Jan;5 (1) :60-5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDC; CK1; p70S6K

• CAS Number:

  [1177141-67-1]